Patent Application: Diabetes Prevention/Treatment by Myeloid Suppressor Cell Activity
Summary
The USPTO has published a new patent application (US20260085291A1) from CREATIVE MEDICAL TECHNOLOGIES, INC. The application details methods and compositions for preventing or treating Type 1 diabetes by augmenting myeloid suppressor cell activity, potentially involving conditioned immune cells or exogenous suppressor cells.
What changed
This document is a published patent application from the USPTO, not a regulatory rule or guidance. It describes a novel approach to preventing or treating Type 1 diabetes by modulating myeloid suppressor cell activity. The proposed methods involve administering immune cells conditioned by exposure to regenerative cells (such as umbilical cord-derived mesenchymal stem cells) or cultured in their presence, potentially combined with agents that enhance myeloid suppressor cell activity or with exogenous suppressor cells.
As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in diabetes treatment and related biotechnologies. Companies in the pharmaceutical and biotechnology sectors, particularly those involved in cell therapy or autoimmune disease research, should monitor the progress of this and similar patent applications as they may indicate emerging therapeutic areas or intellectual property landscapes.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PREVENTION AND/OR TREATMENT OF TYPE 1 DIABETES BY AUGMENTATION OF MYELOID SUPPRESSOR CELL ACTIVITY
Application US20260085291A1 Kind: A1 Mar 26, 2026
Assignee
CREATIVE MEDICAL TECHNOLOGIES, INC.
Inventors
Thomas Ichim, Amit Patel
Abstract
Disclosed are means, methods and compositions of matter useful for prevention and/or reversion of type 1 diabetes by upregulation of myeloid suppressor cell activity in a mammal suffering from and/or at risk of developing type 1 diabetes. In one embodiment the invention teaches administration of immune cells that have been conditioned by exposure to regenerative cells, and/or cultured in the presence of factors produced from regenerative cells. In one embodiment said regenerative cells are umbilical cord derived mesenchymal stem cells. In one embodiment, immune cells that have been exposed to said regenerative cells are administered together with agents known to enhance myeloid suppressor cell activity. In another embodiment immune cells are administered together with exogenous myeloid suppressor cells. 2
CPC Classifications
C12N 5/0662 A61K 40/10 A61K 40/22 A61K 40/416 A61L 27/3834 A61P 3/10 C12N 5/0634 A61K 2239/31 A61K 2239/38
Filing Date
2025-08-19
Application No.
19303763
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.